데노수맙 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "데노수맙" in Korean language version.

refsWebsite

Global rank Korean rank

10nih.gov

4^th place

8doi.org

2^nd place

3^rd place

3archive.org

6^th place

18^th place

2web.archive.org

1^st place

1landesbioscience.com

low place

1europa.eu

68^th place

145^th place

1amgen.com

low place

1drugs.com

399^th place

141^st place

1semanticscholar.org

11^th place

310^th place

1psu.edu

207^th place

220^th place

1todaysgeriatricmedicine.com

low place

amgen.com (Global: low place; Korean: low place)

“Prolia (denosumab)”. 《Products》. Amgen. 2015년 9월 29일에 원본 문서에서 보존된 문서. 2012년 5월 6일에 확인함.

archive.org (Global: 6^th place; Korean: 18^th place)

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH 외 (February 2006). “Denosumab in postmenopausal women with low bone mineral density”. 《The New England Journal of Medicine》 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR 외 (August 2009). “Denosumab for prevention of fractures in postmenopausal women with osteoporosis”. 《The New England Journal of Medicine》 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.
Khosla S (August 2009). “Increasing options for the treatment of osteoporosis”. 《The New England Journal of Medicine》 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.

doi.org (Global: 2^nd place; Korean: 3^rd place)

dx.doi.org

Pageau SC (2009). “Denosumab”. 《mAbs》 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH 외 (February 2006). “Denosumab in postmenopausal women with low bone mineral density”. 《The New England Journal of Medicine》 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA 외 (November 2012). “Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials”. 《European Journal of Cancer》 48 (16): 3082–92. doi:10.1016/j.ejca.2012.08.002. PMID 22975218.
Josse R, Khan A, Ngui D, Shapiro M (March 2013). “Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis”. 《Current Medical Research and Opinion》 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.
Nayak S, Greenspan SL (March 2017). “Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis”. 《Journal of the American Geriatrics Society》 65 (3): 490–495. doi:10.1111/jgs.14668. PMC 5358515. PMID 28304090.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR 외 (August 2009). “Denosumab for prevention of fractures in postmenopausal women with osteoporosis”. 《The New England Journal of Medicine》 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.
Khosla S (August 2009). “Increasing options for the treatment of osteoporosis”. 《The New England Journal of Medicine》 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.
Boyce AM (August 2017). “Denosumab: an Emerging Therapy in Pediatric Bone Disorders”. 《Current Osteoporosis Reports》 15 (4): 283–292. doi:10.1007/s11914-017-0380-1. PMC 5554707. PMID 28643220.

drugs.com (Global: 399^th place; Korean: 141^st place)

“Denosumab”. The American Society of Health-System Pharmacists. 2015년 3월 16일에 확인함.

europa.eu (Global: 68^th place; Korean: 145^th place)

ema.europa.eu

“European Public Assessment Report (EPAR) for Prolia.” (PDF). European Medicines Agency. 2014년 10월 16일. 2016년 3월 4일에 원본 문서 (PDF)에서 보존된 문서. 2022년 12월 29일에 확인함.

landesbioscience.com (Global: low place; Korean: low place)

Pageau SC (2009). “Denosumab”. 《mAbs》 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634.

nih.gov (Global: 4^th place; Korean: 4^th place)

ncbi.nlm.nih.gov

Pageau SC (2009). “Denosumab”. 《mAbs》 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634.
McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH 외 (February 2006). “Denosumab in postmenopausal women with low bone mineral density”. 《The New England Journal of Medicine》 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA 외 (November 2012). “Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials”. 《European Journal of Cancer》 48 (16): 3082–92. doi:10.1016/j.ejca.2012.08.002. PMID 22975218.
Zhou Z, Chen C, Zhang J, Ji X, Liu L, Zhang G 외 (2014). “Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis”. 《International Journal of Clinical and Experimental Pathology》 7 (5): 2113–22. PMC 4069896. PMID 24966919.
Josse R, Khan A, Ngui D, Shapiro M (March 2013). “Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis”. 《Current Medical Research and Opinion》 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.
Nayak S, Greenspan SL (March 2017). “Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis”. 《Journal of the American Geriatrics Society》 65 (3): 490–495. doi:10.1111/jgs.14668. PMC 5358515. PMID 28304090.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR 외 (August 2009). “Denosumab for prevention of fractures in postmenopausal women with osteoporosis”. 《The New England Journal of Medicine》 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.
Khosla S (August 2009). “Increasing options for the treatment of osteoporosis”. 《The New England Journal of Medicine》 361 (8): 818–20. doi:10.1056/NEJMe0905480. PMC 3901579. PMID 19671654.
EntrezGene 8600 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11; Homo sapiens
also known as RANKL. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response.
Boyce AM (August 2017). “Denosumab: an Emerging Therapy in Pediatric Bone Disorders”. 《Current Osteoporosis Reports》 15 (4): 283–292. doi:10.1007/s11914-017-0380-1. PMC 5554707. PMID 28643220.

psu.edu (Global: 207^th place; Korean: 220^th place)

citeseerx.ist.psu.edu

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR 외 (August 2009). “Denosumab for prevention of fractures in postmenopausal women with osteoporosis”. 《The New England Journal of Medicine》 361 (8): 756–65. CiteSeerX 10.1.1.472.3489. doi:10.1056/NEJMoa0809493. PMID 19671655.

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

api.semanticscholar.org

Josse R, Khan A, Ngui D, Shapiro M (March 2013). “Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis”. 《Current Medical Research and Opinion》 29 (3): 205–16. doi:10.1185/03007995.2013.763779. PMID 23297819. S2CID 206967103.

todaysgeriatricmedicine.com (Global: low place; Korean: low place)

“Injectable Prolia — Osteoporosis Update”.

web.archive.org (Global: 1^st place; Korean: 1^st place)

“European Public Assessment Report (EPAR) for Prolia.” (PDF). European Medicines Agency. 2014년 10월 16일. 2016년 3월 4일에 원본 문서 (PDF)에서 보존된 문서. 2022년 12월 29일에 확인함.
“Prolia (denosumab)”. 《Products》. Amgen. 2015년 9월 29일에 원본 문서에서 보존된 문서. 2012년 5월 6일에 확인함.

데노수맙 (Korean Wikipedia)

amgen.com (Global: low place; Korean: low place)

archive.org (Global: 6th place; Korean: 18th place)

doi.org (Global: 2nd place; Korean: 3rd place)

dx.doi.org

drugs.com (Global: 399th place; Korean: 141st place)

europa.eu (Global: 68th place; Korean: 145th place)

ema.europa.eu

landesbioscience.com (Global: low place; Korean: low place)

nih.gov (Global: 4th place; Korean: 4th place)

ncbi.nlm.nih.gov

psu.edu (Global: 207th place; Korean: 220th place)

citeseerx.ist.psu.edu

semanticscholar.org (Global: 11th place; Korean: 310th place)

api.semanticscholar.org

todaysgeriatricmedicine.com (Global: low place; Korean: low place)

web.archive.org (Global: 1st place; Korean: 1st place)

archive.org (Global: 6^th place; Korean: 18^th place)

doi.org (Global: 2^nd place; Korean: 3^rd place)

drugs.com (Global: 399^th place; Korean: 141^st place)

europa.eu (Global: 68^th place; Korean: 145^th place)

nih.gov (Global: 4^th place; Korean: 4^th place)

psu.edu (Global: 207^th place; Korean: 220^th place)

semanticscholar.org (Global: 11^th place; Korean: 310^th place)

web.archive.org (Global: 1^st place; Korean: 1^st place)